SETX and cancer: Collectively, our data demonstrate that continuous cycling of SETX-deficient cells relies on FANCD2-mediated rescue of endogenous RS and chromosome under-replication during mitosis, underscoring the possibility to exploit a novel synthetic proliferation defect for cancer therapy.